SAPHNELO 300 mg/2mL
Anifrolumab-fnia · INJECTION, SOLUTION · AstraZeneca Pharmaceuticals LP
SAPHNELO is a injection, solution containing anifrolumab-fnia at 300 mg/2mL, taken intravenous. Manufactured by AstraZeneca Pharmaceuticals LP.
Key Facts
- Brand Name
- SAPHNELO
- Generic Name
- Anifrolumab-fnia
- NDC Code (Product)
0310-3040- Manufacturer
- AstraZeneca Pharmaceuticals LP
- Strength
- 300 mg/2mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761123
- Drug Class
- Type I Interferon Receptor Antagonist [EPC]
- Marketing Start
- 07/30/2021
Recall History
No Recall HistoryFrequently Asked Questions
What is SAPHNELO used for?
SAPHNELO contains Anifrolumab-fnia. It is a injection, solution taken intravenous. Consult your doctor for specific uses.
Is SAPHNELO a controlled substance?
SAPHNELO is not classified as a controlled substance by the DEA.
What is the generic name for SAPHNELO?
The generic name for SAPHNELO is Anifrolumab-fnia. There are no other listed brand versions of Anifrolumab-fnia.
What is the NDC code for SAPHNELO 300 mg/2mL?
The NDC (National Drug Code) for SAPHNELO 300 mg/2mL is 0310-3040, listed by AstraZeneca Pharmaceuticals LP.
Other SAPHNELO Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)